Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis

Journal of the American Society of Nephrology

Volumn 11, Issue 7, 2000, Pages 1310-1316

  Manley, Harold J ^a,e   Bailie, George R ^a,b   Frye, Reginald ^d   Hess, Lorraine D ^c   Mcgoldrick, M Donald ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c Albany Dialysis Center   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; TOBRAMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MALE; MINIMUM INHIBITORY CONCENTRATION; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL;

EID: 0034086171     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Fried LF, Bernardini J, Johnston JR, Piraino B: Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 7: 2176-2182, 1996
2. Golper TA, Brier ME, Bunke M, Schreiber MJ, Bartlett BK, Hamilton RW, Strife F, Hamburger RJ: Risk factors for peritonitis in long-term peritoneal dialysis: The Network 9 peritonitis and catheter survival studies. Am J Kidney Dis 28: 428-436, 1996
3. Gahrmani N, Gorban-Brennan N, Kliger LS, Finkelstein FO: Infection rates in end-stage renal disease patients treated with CCPD and CAPD using the Ultrabag™ system. Adv Perit Dial 11: 164-167, 1995
4. Keane WF, Alexander SR, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, Huang C-C, Kawaguchi Y, Piraino B, Riella M, Schaefer F, Vas S: Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update. Perit Dial Int 16: 557-573, 1996
5. Lai M-N, Kao M-T, Chen C-C, Cheung S-Y, Chung W-K: Intraperitoneal once-daily dose of cefazolin and gentamicin for treating CAPD peritonitis. Perit Dial Int 17: 87-89, 1997
6. Vas S, Bargman J, Oreopoulos DG: Treatment in PD: Patients of peritonitis caused by Gram-positive organisms with single daily dose of antibiotics. Perit Dial Int 17: 91-94, 1997
7. Bailie GR, Haqqie SS, Eisele G, Gorman T, Low CL: Effectiveness of once-weekly vancomycin and once-daily gentamicin, intraperitoneally, for CAPD peritonitis. Perit Dial Int 15: 269-271, 1995
8. Manley HJ, Bailie GR, Asher RD, Eisele G, Frye RF: Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 19: 65-70, 1999
9. Low CL, Gopalakrishna K, Lye WC: Pharmacokinetics of once-daily IP cefazolin in CAPD patients. Perit Dial Int 19[Suppl 1]: S33, 1999
10. Low CL, Bailie GR, Evans A, Eisele G, Venezia RA: Pharmacokinetics of once-daily IP gentamicin in CAPD patients. Perit Dial Int 16: 379-384, 1996
11. United States Renal Data System: United States Renal Data System 1999 Annual Report, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney, Urologic, and Hematologic Diseases, Bethesda, MD, 1999
12. Bailie GR, Kane MP: Stability of drug additives to peritoneal dialysate. Perit Dial Int 15: 328-335, 1995
13. National Kidney Foundation-Dialysis Outcomes Quality Initiative: Clinical practice guidelines for peritoneal dialysis adequacy. Am J Kidney Dis 30[Suppl 2]: S67-S136, 1997
14. Dudley MN: Use of laboratory test in infectious diseases. In: Pharmacotherapy, a Pathophysiologic Approach, 3rd Ed., edited by Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Norwalk, CT, Appleton & Lange, 1997, pp 1938
15. Nebcin (tobramycin) [package insert]. Indianapolis, IN: Eli Lilly, 1996
16. Grabe DW, Bailie GR, Eisele G, Frye RF: Pharmacokinetics of intermittent intraperitoneal ceftazidime. Am J Kidney Dis 33: 111-117, 1999
17. Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC: Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 33: 66-72, 1983
18. Kaye D, Wenger N, Agarwal B: Pharmacology of intraperitoneal cefazolin in patients undergoing peritoneal dialysis. Antimicrob Agents Chemother 14: 318-321, 1978
19. Morse GD, Apicella MA, Walshe JJ: Absorption of intraperitoneal antibiotics. Drug Intell Clin Pharm 22: 58-61, 1988
20. McCormack JP, Jewesson PJ: A critical reevaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis 14: 320-339, 1992
21. Nikolaidis P, Vas S, Lawson V, Kennedy-Vosu L, Bernard A, Abraham G, Izatt S, Khanna S, Bargman JM, Oreopoulos DG: Is intraperitoneal tobramycin ototoxic in CAPD patients? Perit Dial Int 11: 156-161, 1991